Cubist Pharmaceuticals announced on 30 July that it would spend US$1.6 billion to expand its antibiotics pipeline by buying two companies, Trius Therapeutics, based in San Diego, California, and Optimer Pharmaceuticals of Jersey City, New Jersey. The deal will give Cubist, headquartered in Lexington, Massachusetts, a number of early-stage antibiotic drug candidates, as well as Dificid (fidaxomicin), Optimer's marketed treatment for Clostridium difficile-associated diarrhoea, and tedizolid.
展开▼
